BioCanRx invests $10 million in promising new cancer immunotherapy research and biomanufacturing
(BioCanRx - Canada's Immunotherapy Network) BioCanRx, Canada's Immunotherapy Network, announces funding of $10M for 14 cancer immunotherapy research projects and eight core and biomanufacturing facilities. In addition to BioCanRx's investment, partner contributions of $16.5M increase the investment in Canadian translational cancer immunotherapy research and manufacturing to $26.5M. Projects include cross-disciplinary teams working on new, rational combination approaches and unique cell, vaccine/virus-based and antibody immunotherapies. Investments in Canada's biomanufacturing capacity and point-of-care cell manufacturing w...
Source: EurekAlert! - Social and Behavioral Science - September 22, 2020 Category: International Medicine & Public Health Source Type: news

Health groups urge caution on COVID-19 vaccine
The American College of Radiology is one of almost 100 health organizations...Read more on AuntMinnie.comRelated Reading: ACR to coordinate imaging for large COVID-19 study ACR Data Science Institute drafts model API ACR taps new executive director for Neiman HPI ACR: New USPSTF lung cancer guidelines will save lives ACR, RSNA call on FDA to hold off on autonomous AI (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 21, 2020 Category: Radiology Source Type: news

Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
Basel, 16 September 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the expanded use of CINtec®PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). Additional information from this test supports clinical decisions about which women will benefit most from immediate follow-up. Laboratories can now use CINtecPLUS Cytology to triage positive results from the cobas ® HPV Test run on the fully integrated, automated and high-thr...
Source: Roche Media News - September 16, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
Basel, 16 September 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the expanded use of CINtec®PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). Additional information from this test supports clinical decisions about which women will benefit most from immediate follow-up. Laboratories can now use CINtecPLUS Cytology to triage positive results from the cobas ® HPV Test run on the fully integrated, automated and high-thr...
Source: Roche Investor Update - September 16, 2020 Category: Pharmaceuticals Source Type: news

New targets for melanoma treatment
(Monash University) A collaborative study led by Monash University's Biomedicine Discovery Institute and the Olivia Newton-John Cancer Research Institute (ONJCRI) has uncovered new markers (HLA-associated peptides) that are uniquely present on melanoma tumours and could pave the way for therapeutic vaccines to be developed in the fight against melanoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 16, 2020 Category: International Medicine & Public Health Source Type: news

Safety of Flu Vaccine in Cancer Patients on Pembrolizumab Safety of Flu Vaccine in Cancer Patients on Pembrolizumab
A new study finds that it is safe for pembrolizumab-treated cancer patients to receive an influenza vaccination, with no increase in reported adverse events.Journal of Oncology Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Mesothelioma Trial to Test Cancer Vaccine with Immunotherapy
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - September 14, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

HPV Vaccination Rises Among U.S. Kids, But Many Still Unprotected
MONDAY, Sept. 14, 2020 -- More U.S. kids are getting a recommended vaccine that protects against several cancers -- but there is still much room for improvement, a new study finds. At issue is the vaccine against human papillomavirus (HPV). Certain... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 14, 2020 Category: General Medicine Source Type: news

Brighteon.social BETA site launched; new alternative to Twitter protects freedom of expression on vaccines, cancer cures and pro-liberty speech that's usually banned by Big Tech
(Natural News) All those who grow tired of the relentless, unfair, politically motivated censorship on Twitter now have a new alternative: Brighteon.social has just launched in beta, providing a free speech platform for real people who are tired of the censorship. Brighteon.social is functioning right now in beta mode, with a few hundred users having... (Source: NaturalNews.com)
Source: NaturalNews.com - September 10, 2020 Category: Consumer Health News Source Type: news

Biopharma Leaders Unite To Stand With Science
NEW YORK, September 8, 2020 — The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines. All nine CEOs signed the following pledge: We, the un...
Source: Johnson and Johnson - September 8, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

3M awards philanthropic grant to Tel Aviv University for COVID-19 vaccine research
(American Friends of Tel Aviv University) Science-based technology company 3M has awarded a significant philanthropic research grant of $400,000 to the Shmunis School of Biomedicine and Cancer Research at Tel Aviv University (TAU) to advance scientific knowledge in the global response to the COVID-19 pandemic. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2020 Category: International Medicine & Public Health Source Type: news

Cancer vaccines: not such a long shot
Investors should stay alert for opportunities to finance breakthroughs (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 7, 2020 Category: Pharmaceuticals Source Type: news

NIDCR's Fall 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Fall 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Announces Availability of COVID-19 Research Funding On May 5, NIDCR issued two Notices of Special Interest highlighting the urgent need for research on coronavirus disease 2019. This research may be conducted either via the National Dental PBRN infrastructu...
Source: NIDCR Science News - September 1, 2020 Category: Dentistry Source Type: news

The 2020 We Work for Health Champion Awards showcase the best of our industry
We are living through an extraordinary moment as COVID-19 continues to spread across the United States. During this time, frontline and essential workers across industries have bravely stepped up to meet the urgent needs of our society: from the emergency room to the supermarket to the post office, these everyday heroes deserve our gratitude and praise.At the same time, our industry ’s workforce has met the challenge head on. And thanks to our industry’s dedicated employees, we have taken collaboration to new heights to help ensure patients can continue to access their medicines during COVID-19 while also worki...
Source: The Catalyst - August 27, 2020 Category: Pharmaceuticals Authors: Giovanni Caforio, M.D. Tags: Coronavirus Source Type: news

How Convalescent Plasma Could Help Fight COVID-19
The last time most of us gave any thought to antibodies was probably in high school biology, but we’re getting a crash refresher course thanks to COVID-19. They are, after all, the key to our best defenses against SARS-CoV-2, the virus that’s caused the global pandemic. People who have been infected likely rely on antibodies to recover, and antibodies are what vaccines are designed to produce. Or at least that’s what infectious-disease and public-health experts assume for now. Because SARS-CoV-2 is such a new virus, even the world’s best authorities aren’t yet sure what it will take to build p...
Source: TIME: Health - August 24, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Small change makes cancer vaccine more effective in animal tests
(Thomas Jefferson University) Tweaking the adenovirus spike protein induces a more robust immune reaction for a cancer vaccine against gastric, pancreatic, esophageal and colon malignancies in animal models. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 24, 2020 Category: International Medicine & Public Health Source Type: news

How UCLA scientists are using stem cells to take on COVID-19
As the COVID-19 pandemic rages on, UCLA researchers are rising to the occasion by channeling their specialized expertise to seek new and creative ways to reduce the spread of the virus and save lives. Using years ’ — or even decades’ — worth of knowledge they’ve acquired studying other diseases and biological processes, many of them have shifted their focus to the novel coronavirus, and they’re collaborating across disciplines as they work toward new diagnostic tests, treatments and vaccines.At UCLA, more than 230 research projects, including several being led by members of theEli and Ed...
Source: UCLA Newsroom: Health Sciences - August 20, 2020 Category: Universities & Medical Training Source Type: news

This Trawler ’s Haul: Evidence That Antibodies Block the Coronavirus
Three crew members aboard were spared when the virus spread through the boat. They were the only ones who had antibodies at the beginning of the trip. (Source: NYT Health)
Source: NYT Health - August 19, 2020 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: Coronavirus (2019-nCoV) Antibodies Boats and Boating Immune System Vaccination and Immunization Hutchinson, Fred, Cancer Research Center Abbott Laboratories Seattle (Wash) Source Type: news

HPV vaccination linked to lower risk of precancerous condition
(Wiley) Vaccination against the human papilloma virus (HPV) reduces the risk of a condition that often leads to cervical cancer, according to an analysis of Danish health registry data. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 5, 2020 Category: Cancer & Oncology Source Type: news

ACS Disagrees With CDC on HPV Vaccination in Adults ACS Disagrees With CDC on HPV Vaccination in Adults
The American Cancer Society's new guidance on human papillomavirus vaccination diverges from the Centers for Disease Control and Prevention's recommendations.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 3, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

New Duke vaccine 'works beautifully' against breast cancer
New research out of Duke University could help the thousands of Americans stricken with breast cancer. According to new research conducted at the Duke Cancer Institute, a vaccine developed at the university for breast cancer is part of an "effective" two-drug strategy for fighting against the disease.  This week, research conducted through a clinical trial at Duke was published in Clinical Cancer Research – a journal of the American Association for Cancer Research. According to that research,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 3, 2020 Category: Pharmaceuticals Authors: Seth Thomas Gulledge Source Type: news

2020 Michelson Prizes support groundbreaking research by young scientists
(Human Vaccines Project) The Michelson Medical Research Foundation and the Human Vaccines Project are pleased to announce the 2020 Michelson Prizes for Human Immunology and Vaccine Research and support the outstanding research of two young scientists advancing human immunology, vaccine discovery and immunotherapy across major global diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 3, 2020 Category: Cancer & Oncology Source Type: news

New Duke vaccine 'works beautifully' against breast cancer
New research out of Duke University could help the thousands of Americans stricken with breast cancer. According to new research conducted at the Duke Cancer Institute, a vaccine developed at the university for breast cancer is part of an "effective" two-drug strategy for fighting against the disease.  This week, research conducted through a clinical trial at Duke was published in Clinical Cancer Research – a journal of the American Association for Cancer Research. According to that research,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 2, 2020 Category: Pharmaceuticals Authors: Seth Thomas Gulledge Source Type: news

New Duke vaccine 'works beautifully' against breast cancer
New research out of Duke University could help the thousands of Americans stricken with breast cancer. According to new research conducted at the Duke Cancer Institute, a vaccine developed at the university for breast cancer is part of an "effective" two-drug strategy for fighting against the disease.  This week, research conducted through a clinical trial at Duke was published in Clinical Cancer Research – a journal of the American Association for Cancer Research. According to that research,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 2, 2020 Category: Biotechnology Authors: Seth Thomas Gulledge Source Type: news

Investigational breast cancer vaccine plus immune therapy work well in tandem
(Duke University Medical Center) A vaccine for HER2-positive breast cancers that is being tested in a clinical trial at Duke Cancer Institute is part of an effective, two-drug strategy for enlisting the immune system to fight tumors, according to a Duke-led study in Clinical Cancer Research, a journal of the American Association for Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 30, 2020 Category: Cancer & Oncology Source Type: news

HPV Shots: Safe and Effective, But Many Parents Still Hesitate
WEDNESDAY, July 29, 2020 -- More than a decade of research has shown that the human papillomavirus (HPV) vaccine protects against a host of cancers, yet a new study finds that only half of American teens complete the multiple-shot regimen. Why?... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 29, 2020 Category: General Medicine Source Type: news

Moderna Begins Testing Coronavirus Vaccine On 30,000 Volunteers
CAMBRIDGE (AP) – The world’s biggest COVID-19 vaccine study got underway Monday with the first of 30,000 planned volunteers helping to test shots created by the U.S. government — one of several candidates in the final stretch of the global vaccine race. There’s still no guarantee that the experimental vaccine, developed by the National Institutes of Health and Moderna Inc., will really protect. The needed proof: Volunteers won’t know if they’re getting the real shot or a dummy version. After two doses, scientists will closely track which group experiences more infections as they go about...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 27, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Business Covid-19 Boston, MA Featured Health Healthcare Status Syndicated CBSN Boston Coronavirus Coronavirus Vaccine Moderna Moderna Therapeutics Source Type: news

Inside the Global Quest to Trace the Origins of COVID-19 —and Predict Where It Will Go Next
It wasn’t greed, or curiosity, that made Li Rusheng grab his shotgun and enter Shitou Cave. It was about survival. During Mao-era collectivization of the early 1970s, food was so scarce in the emerald valleys of southwestern China’s Yunnan province that farmers like Li could expect to eat meat only once a year–if they were lucky. So, craving protein, Li and his friends would sneak into the cave to hunt the creatures they could hear squeaking and fluttering inside: bats. Li would creep into the gloom and fire blindly at the vaulted ceiling, picking up any quarry that fell to the ground, while his companion...
Source: TIME: Health - July 23, 2020 Category: Consumer Health News Authors: Charlie Campbell/ Yuxi, Yunnan and Alice Park Tags: Uncategorized COVID-19 feature Magazine Source Type: news

DR MARTIN SCURR answers your health questions
DR MARTIN SCURR: Should I pay privately to have my teenage son vaccinated against HPV? I have just read that this virus is linked to prostate cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - July 21, 2020 Category: Consumer Health News Source Type: news

Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration
Fusobacterium nucleatum is implicated in accelerating colorectal cancer (CRC) and is found within metastatic CRC cells in patient biopsies. Here, we found that bacterial invasion of CRC cells and cocultured immune cells induced a differential cytokine secretion that may contribute to CRC metastasis. We used a modified galactose kinase markerless gene deletion approach and found that F. nucleatum invaded cultured HCT116 CRC cells through the bacterial surface adhesin Fap2. In turn, Fap2-dependent invasion induced the secretion of the proinflammatory cytokines IL-8 and CXCL1, which are associated with CRC progression and pro...
Source: Signal Transduction Knowledge Environment - July 21, 2020 Category: Science Authors: Casasanta, M. A., Yoo, C. C., Udayasuryan, B., Sanders, B. E., Umana, A., Zhang, Y., Peng, H., Duncan, A. J., Wang, Y., Li, L., Verbridge, S. S., Slade, D. J. Tags: STKE Research Articles Source Type: news

American Cancer Soc. Advises Offering HPV Vaccine Starting at Age 9 or 10 American Cancer Soc. Advises Offering HPV Vaccine Starting at Age 9 or 10
In an adaptation to the current Advisory Committee on Immunization Practices recommendation, the American Cancer Society encourages healthcare providers to offer the HPV vaccine at age 9 or 10 years.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 16, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

Better vaccines are in our blood
(Wyss Institute for Biologically Inspired Engineering at Harvard) Red blood cells don't just shuttle oxygen from our lungs to our organs: they also help the body fight off infections by capturing pathogens in the blood and presenting them to immune cells in the spleen. Researchers from the Wyss Institute and Harvard SEAS have harnessed this innate ability to create a technology that uses red blood cells to   initiate a strong immune response against an antigen without the need for a foreign adjuvant, setting the stage for safer, more effective vaccines. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 13, 2020 Category: Cancer & Oncology Source Type: news

Potential causal role of human papilloma viruses (HPVs) in prostate cancers
(BMC (BioMed Central)) Human papilloma viruses (HPVs) - a common group of viruses known to cause cervical cancers - may also have a causal role in prostate cancer, according to a literature review published in the open access journal Infectious Agents and Cancer, supporting the case for universal HPV vaccination. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 13, 2020 Category: Cancer & Oncology Source Type: news

Here ’ s How To Volunteer For A Coronavirus Vaccine Trial
(CNN) — If you want to be one of the first to receive an experimental vaccine for Covid-19, now’s your chance. Wednesday, a new website — coronaviruspreventionnetwork.org — went live allowing people in the United States to register to take part in clinical trials for vaccines and monoclonal antibody therapies. The website will handle registration for the four large vaccine studies that are expected to start this summer and fall, and any others that follow. The US Department of Health and Human Services announced the website Wednesday, along with the appointment of the Fred Hutchinson Cancer Research...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 10, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health CNN Coronavirus Coronavirus Vaccine Source Type: news

Breakthrough with cancer vaccine
(Translational Research Institute) Scientists have developed a new cancer vaccine with the potential to activate the body's immune system to fight a range of cancers, including leukaemia, breast cancer, lung cancer and pancreatic cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2020 Category: Cancer & Oncology Source Type: news

American Cancer Society Updates HPV Vaccination Guidelines
WEDNESDAY, July 8, 2020 -- The American Cancer Society has updated guidelines on human papillomavirus (HPV) vaccination, emphasizing that vaccination should be routinely offered at age 9 to 12 years; the updated recommendations were published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 8, 2020 Category: Pharmaceuticals Source Type: news

Study: 'Anti-vaxxers' gain traction against HPV vaccine on Facebook
(University of Missouri-Columbia) One of the biggest social media sites -- Facebook -- has allowed " anti-vaxxers " to gain a stronger voice against the use of the human papillomavirus, or HPV, vaccine, according to a new study from a media expert at the University of Missouri. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 8, 2020 Category: Cancer & Oncology Source Type: news

American Cancer Society updates guideline for HPV vaccination
(American Cancer Society) The American Cancer Society has updated its guideline for HPV vaccination, adapting a 2019 update from the Federal Advisory Committee on Immunization Practices. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 8, 2020 Category: Cancer & Oncology Source Type: news

Fred Hutch joins international COVID-19 vaccine effort
(Fred Hutchinson Cancer Research Center) Fred Hutchinson Cancer Research Center has been named the coordinating center for vaccine clinical trials of the COVID-19 Prevention Network (COVPN), funded by the National Institute of Allergy and Infectious Diseases. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 8, 2020 Category: Infectious Diseases Source Type: news

Biotech's surge pushes Bay Area companies — including a Covid drug hopeful — toward collective $1 billion in fresh funds
Three pending Bay Area biotech IPOs and follow-on offerings from four other drug makers could collectively raise more than $1.1 billion, highlighting biotech's latest Wall Street resurgence amid hope for new cancer treatments and drugs and vaccines targeting Covid-19. Annexon Inc., which said last week that it raised $100 million, marked its place for an initial public offering of $100 million filing as Nurix Therapeutics Inc. declared its intentions for a $100 million IPO and Nkarta Inc. detailed… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 7, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Tiny mineral particles are better vehicles for promising gene therapy
(University of Wisconsin-Madison) University of Wisconsin-Madison researchers have developed a safer and more efficient way to deliver a promising new method for treating cancer and liver disorders and for vaccination -- including a COVID-19 vaccine from Moderna Therapeutics that has advanced to clinical trials with humans. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 2, 2020 Category: Cancer & Oncology Source Type: news

School HPV vaccine policies could result in higher vaccination rates, reduction in cancers
FINDINGSA UCLA-led study has found that in 2 of 3 states and jurisdictions with policies that require students entering school to receive the human papillomavirus vaccine, vaccination rates among 13-to-17-year-olds were significantly higher than in surrounding states without such policies.In Rhode Island, the vaccination rate among adolescents was 91%, compared with an average of 78% in neighboring non-policy states. In the District of Columbia, the rate was 89%, compared with 72% for nearby non-policy states. Virginia, which is in the same region as the district, was the one state with a vaccination policy that showed no ...
Source: UCLA Newsroom: Health Sciences - June 29, 2020 Category: Universities & Medical Training Source Type: news

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, PENNSYLVANIA, June 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE.The decision is based on data from a pre-planned interim efficacy analysis. Interim safety findings were consistent with the known safety profile of STELARA, and no new safety signals were identified. Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyze the totality of...
Source: Johnson and Johnson - June 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Researchers use stem cells to model the immune response to COVID-19
Editor ’s note: This announcement was updated on June 23, 2020, to correct the value of a grant from the California Institute for Regenerative Medicine. The grant amount was $150,000. Cities across the United States are opening back up, but we ’re still a long way from making the COVID-19 pandemic history. To truly accomplish that, we need to have a vaccine that can stop the spread of infection.But to develop an effective vaccine, we need to understand how the immune system responds to SARS-CoV-2, the virus that causes COVID-19.Vaccines work by imitating infection. They expose a person ’s immune syst...
Source: UCLA Newsroom: Health Sciences - June 23, 2020 Category: Universities & Medical Training Source Type: news

Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L
SAN DIEGO, June 23, 2020 -- (Healthcare Sales & Marketing Network) -- Polynoma LLC, a U.S. immuno-oncology focused biopharmaceutical company and wholly-owned subsidiary of Hong Kong-listed CK Life Sciences Int'l., (Holdings) Inc., announces that the U.S. ... Biopharmaceuticals, Oncology, FDA Polynoma, Seviprotimut-L, Melanoma, Cancer Vaccine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 23, 2020 Category: Pharmaceuticals Source Type: news

Flu vaccine associated with small increased risk for subdeltoid bursitis
(American College of Physicians) Influenza vaccination was associated with a small risk for subdetltoid bursitis in a large retrospective cohort study, an association that was previously supported by clinical evidence from case reports. Education and training on proper injection technique could prevent this adverse event. Findings are published in Annals of Internal Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 22, 2020 Category: Cancer & Oncology Source Type: news

Early clinical trial supports tumor cell-based vaccine for mantle cell lymphoma
(Rockefeller University Press) A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient's own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment. The study, which will be published June 19 in the Journal of Experimental Medicine (JEM), reveals that the vaccines are a safe and effective way to induce the body's immune system to attack any tumor cells that could cause disease relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 19, 2020 Category: Cancer & Oncology Source Type: news

FDA Approves HPV Vaccine Gardasil As Throat Cancer Prevention
The HPV vaccine (Gardasil 9) has been approved by the Food and Drug Administration (FDA) for males and females ages 9 to 45 years to prevent HPV-related genital tract and anogenital infections and cancers for several years. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 17, 2020 Category: Pharmaceuticals Authors: Nina Shapiro, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news

UCLA Mattel Children ’s Hospital rated among best children’s hospitals in U.S.
UCLA Mattel Children ’s Hospital has been recognized for itsbroad excellence in pediatric care inthe 2020 –21 Best Children ’s Hospitals rankings, published today by U.S. News& World Report.The hospital rankedamong the best in the nation in seven pediatric specialties:diabetes and endocrinology,neonatology,cancer,neurology andneurosurgery,  nephrology,gastroenterology andgastrointestinal surgery, andorthopedics.“It’s a privilege to be recognized for the extraordinary contributions of our physicians, nurses, therapists and highly skilled team of healt...
Source: UCLA Newsroom: Health Sciences - June 16, 2020 Category: Universities & Medical Training Source Type: news